Get started
Author

Jiye Ahn

Observed names: Ji-Ye Ahn, JiYe Ahn
OpenAlex ID: A5016523760
A novel 3,4-dihydropyrimidin-2(1H)-one: HIV-1 replication inhibitors with improved metabolic stability
2012 · Junwon Kim, Taedong Ok, et al. · Bioorganic & Medicinal Chemistry Letters · 56
Safety, Tolerability, and Pharmacokinetics of Telacebec (Q203), a New Antituberculosis Agent, in Healthy Subjects
2021 · Jeongjun Kim, Jinho Choi, et al. · Antimicrobial Agents and Chemotherapy · 40
GM-CSF and IL-4 produced by NKT cells inversely regulate IL-1β production by macrophages
2017 · Sehee Ahn, Dongjin Jeong, et al. · Immunology Letters · 22
Synthesis and biological evaluation of triazolothienopyrimidine derivatives as novel HIV-1 replication inhibitors
2012 · Junwon Kim, Jeongjin Kwon, et al. · Bioorganic & Medicinal Chemistry Letters · 21
Safety, Tolerability, Pharmacokinetics, and Metabolism of Telacebec (Q203) for the Treatment of Tuberculosis: a Randomized, Placebo-Controlled, Multiple Ascending Dose Phase 1B Trial
2022 · Jeongjun Kim, Jinho Choi, et al. · Antimicrobial Agents and Chemotherapy · 16
Serendipitous discovery of 2-((phenylsulfonyl)methyl)-thieno[3,2-d]pyrimidine derivatives as novel HIV-1 replication inhibitors
2014 · Junwon Kim, Jeongjin Kwon, et al. · Bioorganic & Medicinal Chemistry Letters · 14
Suppression Effect of Gray Mold and Late Blight on Tomato Plants by Rhamnolipid B
2009 · Ji-Ye Ahn, Myung-Soo Park, et al. · Research in Plant Disease · 5
PDF
A first-in-human trial of selective CDK7 inhibitor Q901, in patients with advanced solid tumors: Interim results of a phase I study (QRNT-009).
2024 · Hao Xie, Anthony B. El-Khoueiry, et al. · Journal of Clinical Oncology · 4
PDF
Abstract 2255: Patient pharmacodynamic biomarker and pk evaluation results from an ongoing phase I dose-escalation study of q702, an axl, mer and csf1r kinase inhibitor in patients with advanced solid tumors
2023 · Bae Jung Choi, Devalingam Devalingam, et al. · Cancer Research · 4
Abstract 5712: Functional dissection of CDK7 in transcription using a highly selective CDK7 inhibitor Q901
2024 · Hyerim Jung, Dahun Um, et al. · Cancer Research · 1
A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.
2021 · Angela Tatiana Alistar, Anthony B. El-Khoueiry, et al. · Journal of Clinical Oncology · 1
Abstract A009: Preclinical safety and efficacy QP101: A novel HER2-targeting dual payload ADC combining topoisomerase I (TOP1) and cyclin dependent kinase 7 (CDK7) inhibitors
2026 · Kiyean Nam, Hwankyu Kang, et al. · Clinical Cancer Research
645 A phase 1B/2, open-label study of Q702 in combination with intravenous pembrolizumab in patients with selected advanced solid tumors
2023 · Seung-Tae Kim, Hong Jae Chon, et al. · Regular and Young Investigator Award Abstracts
PDF
651 A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors
2023 · Devalingam Mahalingam, Angela Alistar, et al. · Regular and Young Investigator Award Abstracts
PDF
Abstract A205: Q701, a selective Axl and Mer inhibitor as an immune checkpoint inhibitor
2018 · Yeong-In Yang, Hwankyu Kang, et al. · Molecular Cancer Therapeutics
Abstract B162: Highly selective, orally available CDK7 inhibitor for cancer therapy
2018 · Yeejin Jeon, Donghoon Yu, et al. · Molecular Cancer Therapeutics
Works count: 16
Citation count: 184
H-index: 6
I10-index: 6
Year
Topic
Type